The Male Hypogonadism drugs in development market research report provides comprehensive information on the therapeutics under development for Male Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Male Hypogonadism. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Male Hypogonadism by 15 companies/universities/institutes. The top development phase for Male Hypogonadism is phase ii with five drugs in that stage. The Male Hypogonadism pipeline has 14 drugs in development by companies and one by universities/ institutes. Some of the companies in the Male Hypogonadism pipeline products market are: Transdermal Delivery Solutions, Massachusetts General Hospital and Shenzhen Salubris Pharmaceuticals.
The key targets in the Male Hypogonadism pipeline products market include Androgen Receptor, Follicle Stimulating Hormone Receptor, and Estrogen Receptor.
The key mechanisms of action in the Male Hypogonadism pipeline product include Androgen Receptor Agonist with ten drugs in Pre-Registration. The Male Hypogonadism pipeline products include nine routes of administration with the top ROA being Oral and four key molecule types in the Male Hypogonadism pipeline products market including Small Molecule, and Synthetic Peptide.
Male Hypogonadism overview
Male hypogonadism is a condition in which the body doesn’t produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass, and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles, and untreated sleep apnea. Treatment includes hormone replacement.
For a complete picture of Male Hypogonadism’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
